Senores Pharma expects to cross ₹3,000 crore revenue early
In short
Senores Pharmaceuticals expects to cross its ₹3,000 crore revenue target ahead of schedule. The company says growth should come from new US subsidiaries, 12 ANDA launches, CDMO expansion and a pipeline of more than 116 products.
It also expects 25-30% annual revenue growth and better profitability. That points to a stronger business outlook for the pharma company.
What the reporting says
Senores Pharmaceuticals expects to cross its ₹3,000 crore revenue target ahead of schedule, according to a CNBC TV18 Business summary citing Managing Director Swapnil Shah. Growth is expected from new US subsidiaries, 12 ANDA launches, expanding CDMO operations and a pipeline of more than 116 products. The company also expects 25-30% annual revenue growth and improving profitability.
Why it matters
A CNBC TV18 Business summary quotes Managing Director Swapnil Shah as saying Senores Pharmaceuticals expects to cross its ₹3,000 crore revenue target ahead of schedule. The growth plan includes new US subsidiaries, 12 ANDA launches, expanding CDMO operations and a pipeline of over 116 products. The company also expects 25-30% annual revenue growth and improving profitability, which is relevant to pharma investors.